Abhishek Goyal 1 , Mary Beth Terry 2 , Zhezhen Jin 3 , Abby B Siegel 4 Show Affiliations »
Abstract
BACKGROUND: Chronic inflammation has been associated with colorectal cancer. Prediagnostic levels of C-reactive protein (CRP), a highly sensitive marker of inflammation, have been weakly associated with increased colorectal cancer incidence, but few data are available examining its relationship with colorectal cancer mortality. METHODS: In the Third National Health and Nutrition Examination Survey (NHANES III), 65% of the 15,924 adult participants had CRP levels ≤0.21 mg/dL. Using this as the reference group, we calculated hazard ratios (HR) for higher CRP categories and colorectal cancer mortality, and compared them with HRs for other mortality causes. RESULTS: Over a median follow-up period of 14.2 years, there were 92 deaths from colorectal cancer. Compared with the reference group, multivariable adjusted HRs for colorectal cancer mortality were 2.66 [95% confidence interval (CI), 1.36-5.20] for CRP levels 0.22-0.50 mg/dL; 3.40 (95% CI, 1.48-7.77) for levels 0.51-1.00 mg/dL; and 3.96 (95% CI, 1.64-9.52) for levels >1.00 mg/dL. Estimates for colorectal cancer mortality did not change appreciably after excluding deaths within the first 3 years or by limiting follow-up to 5 or 10 years. CONCLUSIONS: In a large representative study of U.S. adults, we observed strong dose-response associations between CRP levels and colorectal cancer mortality. IMPACT: Further evaluation of CRP may help identify high-risk groups for colorectal cancer screening and those who might benefit most from prophylactic anti-inflammatory therapy. ©2014 American Association for Cancer Research.
BACKGROUND: Chronic inflammation has been associated with colorectal cancer . Prediagnostic levels of C-reactive protein (CRP ), a highly sensitive marker of inflammation , have been weakly associated with increased colorectal cancer incidence, but few data are available examining its relationship with colorectal cancer mortality. METHODS: In the Third National Health and Nutrition Examination Survey (NHANES III), 65% of the 15,924 adult participants had CRP levels ≤0.21 mg/dL. Using this as the reference group, we calculated hazard ratios (HR) for higher CRP categories and colorectal cancer mortality, and compared them with HRs for other mortality causes. RESULTS: Over a median follow-up period of 14.2 years, there were 92 deaths from colorectal cancer . Compared with the reference group, multivariable adjusted HRs for colorectal cancer mortality were 2.66 [95% confidence interval (CI), 1.36-5.20] for CRP levels 0.22-0.50 mg/dL; 3.40 (95% CI, 1.48-7.77) for levels 0.51-1.00 mg/dL; and 3.96 (95% CI, 1.64-9.52) for levels >1.00 mg/dL. Estimates for colorectal cancer mortality did not change appreciably after excluding deaths within the first 3 years or by limiting follow-up to 5 or 10 years. CONCLUSIONS: In a large representative study of U.S. adults, we observed strong dose-response associations between CRP levels and colorectal cancer mortality. IMPACT: Further evaluation of CRP may help identify high-risk groups for colorectal cancer screening and those who might benefit most from prophylactic anti-inflammatory therapy. ©2014 American Association for Cancer Research.
Entities: Disease
Gene
Species
Mesh： See more »
Substances： See more »
Year: 2014
PMID： 24867266 DOI： 10.1158/1055-9965.EPI-13-0577
Source DB: PubMed Journal: Cancer Epidemiol Biomarkers Prev ISSN： 1055-9965 Impact factor: 4.254